Filter by
Filter by
Hypofractionated Proton Therapy in Early Prostate Cancer: Results of a Phase I/II Trial at Loma Linda University.
A cohort of 146 patients with low-risk prostate cancer were treated to 60 Gy (cobalt Gy equivalent) of proton therapy (20 fractions of 3.0 Gy per fraction) in 4...
High-dose conformal proton therapy for clinical perineural invasion in cutaneous head and neck cancer.
Perineural invasion (PNI) is an uncommon (<5%) which refers to tumor cell invasion extensive enough to cause clinically detectable deficits of the involved...
Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
This study by MGH retrospectively analyzed 66 patients with unresectable intrahepatic cholangiocarcinoma (ICC) who were treated with hypofractionated proton (32...
Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma.
Published by the NCC group in Korea, this study reported outcomes of 45 patients including 37 had recurrent and/or residual disease treated with PBT to a total...
Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group.
This study analyzed the data of 63 patients with liver tumors treated with PBT. Hypofractionated PBT resulted in excellent local control, sparing of the...
Extreme hypofractionated proton radiotherapy for prostate cancer using pencil beam scanning: Dosimetry, acute toxicity and preliminary results.
A study by the research group in Prague. Two hundred patients with early-stage prostate cancer were treated with IMPT on extreme hypofractionated schedule (36...
Initial toxicity, QoL outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated vs. standard fractionated PT for low-risk prostate cancer
A multi-center prospective phase 3 randomized trial aimed to identify differences in toxicity and quality-of-life outcomes between standard fractionation and...